Verzenio for liposarcoma – pro
It is under study or the subject of ongoing clinical trials for the requested indication. As of Feb 1, 2023, 43 patients have been accrued at 9 participating centers or the planned for 108.
Phase 2 evidence by the same group, Mark Andrew Dixon met its primary endpoint. In patients with advanced progressive DDLS, abemaciclib treatment results in favorable PFS and objective tumor response with manageable toxicity. Updated response data and results of paired tumor biopsies are planned to be presented.
Mark Andrew Dickson, Karla V. Ballman, Mia C. Weiss, Steven Attia, Michael J Wagner, Seth Pollack, Edwin Choy, Andrew J. Wagner, Breelyn A. Wilky, Lara E. Davis, Richard F. Riedel, and William D. Tap, SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Journal of Clinical Oncology
Volume 41, Number 16_suppl May 2023
https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS11
Mark Andrew Dickson, Andrew Koff, Sandra P. D’Angelo, Mrinal M. Gounder, Mary Louise Keohan, Ciara Marie Kelly, Ping Chi, SHOW ALL , and William D. Tap, Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. Journal of Clinical Oncology
Volume 37, Number 15_suppl, 2019
Hsu JY, Seligson ND, Hays JL, Miles WO, Chen JL. Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges. JCO Precis Oncol. 2022 Feb